Personalized Medicine

Screening for Pancreatic Cancer Is Effective, Has Value— at Least in High-Risk Individuals

Caroline Helwick

August 2011, Vol 2, No 5 - Cancer Care

Ongoing efforts to screen asymptomatic persons for pancreatic cancer have been unsuccessful, but targeting persons at high risk for the disease appears to be clinically effective as well as cost-effective.

Researchers have combined the use of a serum biomarker, CA 19-9, and endoscopic ultrasonography to create a screening protocol for persons at risk for the malignancy on the basis of family history and age and reported their results in the July issue of Gastro - intestinal Endoscopy (Zubarik R, et al. Gastrointest Endosc. 2011;74:87-95).

[ Read More ]

Dose-Monitoring, Split-Fill Programs Reduce Oral Chemotherapy Waste, Save Costs

Caroline Helwick

August 2011, Vol 2, No 5 - Oncology

Dose-monitoring programs for oral chemotherapy drugs can reduce wastage and reduce the risk of serious adverse effects associated with these drugs. This translates into cost-savings for patients and for payers of >$2500 per patient, suggested researchers from Walgreens Specialty Pharmacy.

The company developed an oral chemotherapy cycle management program (CMP) that offers a “split-fill” option and close monitoring of pa - tients for adverse events. This is an optional program, and payers can elect to participate.

[ Read More ]

Northwestern University Comprehensive Cancer Center

August 2011, Vol 2, No 5 - Oncology

Interview with Al B. Benson III, MD, FACP

Professor of Medicine and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL


Q: How would you define the concept of best practices, and what makes an oncology center, such as the Northwestern University Robert H. Lurie Comprehensive Cancer Center, be among the best oncology practices in the country?

[ Read More ]

The Impact of Therapy Type on Clinical Fragmentation in Oncology Care

Wayne Kuznar

July 2011, Vol 2, No 4 - Oncology

Philadelphia, PA—Fragmentation in oncology care significantly influences physicians’, payers’, and patients’ understanding of how cancer therapies lead to improved quality of care. The main reason for fragmentation is the challenge in linking pharmacy and medical data in a way that generates usable information, according to Atheer A. Kaddis, PharmD, Vice President, Managed Markets, Diplomat Specialty Pharmacy. [ Read More ]

A New Option for Metastatic Breast Cancer

Wayne Kuznar

July 2011, Vol 2, No 4 - Breast Cancer

Philadelphia, PA—The new biologic therapy eribulin (Halaven) was recently approved by the US Food and Drug Administration for the treatment of patients with metastatic breast cancer. Stephen C. Malamud, MD, Attending Physician, Beth Israel Medical Center, New York City, discussed the benefits and risks associated with this new treatment option at a special session during the meeting.

[ Read More ]